Field Trip’s psychedelic compound produces a two to four hour trip, half the duration of psilocybin

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. (FTRP) has completed the initial drug metabolism and pharmacokinetic (DMPK) studies for its psychedelic compound FT-104. The studies found that the psychedelic effects from FT-104 last for just two to four hours, about half the time as a psilocybin trip, making it more “clinically efficient and accessible”. Field Trip is now looking to apply for Phase 1 human trials after confirming that the compound is easy to synthesize and has low risk for addiction.

PDF of article